Cimduo Approval History
- FDA approved: Yes (First approved February 28, 2018)
- Brand name: Cimduo
- Generic name: lamivudine and tenofovir disoproxil fumarate
- Dosage form: Tablets
- Company: Mylan Pharmaceuticals Inc.
- Treatment for: HIV Infection
Cimduo (lamivudine and tenofovir disoproxil fumarate) is a combination of two nucleo(t)side reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Development History and FDA Approval Process for Cimduo
|Mar 2, 2018||Mylan to Introduce Cimduo (lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.